Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Mar 7, 2017
    RedHill and Concordia recently entered into an exclusive co-promotion agreement, granting RedHill certain promotion rights in the U.S. for Donnatal®RedHill expects to initiate promotion of Donnatal® in the second quarter of 2017TEL-AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHil...
    PDF
    Feb 23, 2017
    TEL-AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Feb 23, 2017
    RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization plans Select 2016 milestones include: Successful final results from the first Phase III study with RHB-105 for the treatme...
    PDF
    Feb 21, 2017
    Top-line results are expected in the second quarter of 2017  The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24 mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute gastroenteritis and gastritis are inflammations of the mucus membranes of the gastroin...
    PDF
    Feb 16, 2017
    TEL-AVIV, Israel, Feb. 16, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Feb 13, 2017
    Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute gastroenteritis and gastritis are inflammations of the mucus membranes of the gast...
    PDF
    Feb 6, 2017
    TEL-AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Jan 12, 2017
    TEL-AVIV, Israel, Jan. 12, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory disea...
    PDF
    Jan 11, 2017
    RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection     Under FDA's Generating Antibiotic Incentives Now (GAIN) Act, QIDP designation allows for Fast-Track status and Priority Review, potentially leading to a shorter NDA review time by th...
    PDF
    Jan 10, 2017
    The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteersThe confirmatory Phase III study with RHB-105 for H. pylori infection is planned to be initiated, subj...
    PDF
    Page: FirstPrevious
    3
    ... NextLast

    Subscribe to press releases